A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis

被引：26

作者：

Alicandro, G. ^{[1
]}

Faelli, N. ^{[1
]}

Gagliardini, R. ^{[2
]}

Santini, B. ^{[3
,4
]}

Magazzu, G. ^{[5
,6
]}

Biffi, A. ^{[1
]}

Rise, P. ^{[7
]}

Galli, C. ^{[7
]}

Tirelli, A. S. ^{[8
]}

Loi, S. ^{[1
]}

Valmarana, L. ^{[1
]}

Cirilli, N. ^{[2
]}

Palmas, T. ^{[3
,4
]}

Vieni, G. ^{[5
,6
]}

Bianchi, M. L. ^{[9
]}

Agostoni, C. ^{[10
]}

Colombo, C. ^{[1
]}

机构：

[1] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Ctr Fibrosi Cist, I-20122 Milan, Italy

[2] AOU Osped Riuniti, Dipartimento Materno Infantile, Ctr Fibrosi Cist, Ancona, Italy

[3] Univ Turin, Dipartimento Pediat, SS Dip Dietet & Nutr Clin, Turin, Italy

[4] Ctr Fibrosi Cist OIRM, Turin, Italy

[5] Univ Messina, Ctr Fibrosi Cist, Messina, Italy

[6] Univ Messina, Unita Gastroenterol Pediat, Messina, Italy

[7] Univ Milan, Dipartimento Sci Farmacol, Milan, Italy

[8] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Lab Anal Chim Clin & Microbiol, Milan, Italy

[9] Ist Auxol Italiano IRCCS, Ctr Malattie Metab Ossee, Milan, Italy

[10] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dipartimento Pediat, Milan, Italy

来源：

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 2013年 / 88卷 / 02期

关键词：

Cystic fibrosis; Docosahexaenoic acid; Supplementation; Plasma fatty acids; Randomised clinical trial; POLYUNSATURATED FATTY-ACIDS; PANCREATIC INSUFFICIENCY; BODY-COMPOSITION; LIPID MEDIATORS; YOUNG-PATIENTS; LINOLEIC-ACID; OMEGA-3-FATTY-ACIDS; DIETARY; ADULTS; N-3;

D O I：

10.1016/j.plefa.2012.10.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Low plasma concentrations of docosahexaenoic acid (DHA) are reported in unsupplemented cystic fibrosis (CF) patients. Forty-one CF patients aged from 6 to 12 years were randomized to receive high-dose DHA (100 mg/kg/day in the first month and 1 g per day thereafter through a 12-month supplementation) or placebo (germ oil). Primary outcome was percentage change in plasma AA:DHA ratio. Secondary outcomes were changes in the number of pulmonary exacerbations compared to previous year, lung function, BMI, skinfold thicknesses, and body composition assessed by DXA and in serum concentrations of C-reactive protein, cytokines and vitamin (alpha-tocopherol and retinol). Compared to the control group plasma AA:DHA ratio decreased in the intervention group after 6 months (median percentage changes: -73% in the intervention group vs. -10% in the control group, P=0.001). No differences were detected between groups for secondary outcomes. Despite a decrease of the AA/DHA ratio, DHA supplementation for one year did not induce any significant biochemical and clinical improvement in CF patients. (c) 2012 Elsevier Ltd. All rights reserved.

引用

页码：163 / 169

页数：7

共 40 条

[1] A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA [J].